Protective activity of silipide on liver damage in rodents.
The activity of silipide, a silybin-phosphatidylcholine complex (IdB 1016), was tested in different models of liver damage in rodents. After oral administration, silipide exhibited a significant and dose-related protective effect against the hepatotoxicity induced by CCl4, praseodymium, ethanol and galactosamine. The ED50 values for inhibition of the rise in ASAT and ALAT levels caused by CCl4 and praseodymium and for antagonism of the increase in liver triglycerides caused by ethanol ranged from 93 to 156 mg/kg (as silybin). At a dose of 400 mg/kg (as silybin), silipide was also active in protecting against paracetamol-induced hepatotoxicity. Silybin and phosphatidylcholine at doses equivalent to those contained in the active doses of silipide failed to show any significant protective activity in these models. The liver protective effect of silipide is probably related to its antioxidant activities and to a stimulating effect on the hepatic synthesis of RNA and proteins.
Conti
M
M
Inverni della Beffa Research and Development Laboratories, Milan, Italy.
Malandrino
S
S
Magistretti
M J
MJ
D000082:Acetaminophen / Q000633:toxicity; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002252:Carbon Tetrachloride Poisoning / Q000473:pathology / Q000517:prevention & control; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology / Q000517:prevention & control*; D000431:Ethanol / Q000633:toxicity; D005260:Female; D005688:Galactosamine / Q000633:toxicity; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D011221:Praseodymium / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012838:Silymarin / Q000627:therapeutic use*
D010713:Phosphatidylcholines; D012838:Silymarin; C067772:IdB 1016; D000082:Acetaminophen; D000431:Ethanol; D005688:Galactosamine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D011221:Praseodymium